Hormonal
Genetically modeled GLP-1 and GIP receptor agonism reduces the risk of Non-Alcoholic Fatty Liver Disease (NAFLD) and lowers ALT levels.
Genetic evidence suggests that activating GLP-1 and GIP receptors improves liver health by reducing the risk of NAFLD and lowering ALT levels. This benefit is independent of alcohol consumption, suggesting a direct metabolic effect on the liver.
For liver health, HbA1c lowering via GIPR/GLP1R was associated with reduced NAFLD (β = −0.34, [−0.50, −0.18], P = 2.74 × 10−5) and lower ALT levels (β = −0.26, [−0.38, −0.15], P = 8.39 × 10−6), with replication supporting these findings.
Why this rating
High-quality Mendelian Randomization with replication across independent cohorts and ancestry groups, though observational in nature.
Source
Genetically modeled GLP1R and GIPR agonism reduce binge drinking and alcohol-associated phenotypes: a multi-ancestry drug-target Mendelian randomization study
Joshua Reitz et al. · Molecular Psychiatry · 2025
DOI 10.1038/s41380-025-03199-3
More from this paper
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →